ThinkCyte and Axcelead DDP collaborate to advance novel phenotypic screening methods
Tokyo and Fujisawa, Japan. December 27, 2022: ThinkCyte …
Axcelead Drug Discovery Partners, Inc. has become a certified provider of spatial transcriptomics technology, Visium, from 10x Genomics
We’re delighted to announce that we have received …
Axcelead DDP and Knowledge Palette Enter into a Collaborative Research Contract on Gene Expression Analysis Concerning Drug-Resistant Cancer
Axcelead Drug Discovery Partners Inc. (headquarters: Fujisawa, Kanagawa; …
Dr. Hideo Fukui will chair the international symposium about new modalities at the American College of Toxicology 2022 annual meeting.
The American College of Toxicology 2022 annual meeting …
Axcelead Drug Discovery Partners and Acadia Pharmaceuticals Launch Drug Discovery Collaboration in Neuroscience
October 5, 2022 – Axcelead Drug Discovery Partners …
Epigeneron and Axcelead DDP singed a master collaboration agreement on drug discovery research for novel drug targets
Epigeneron Inc., (Headquarters: Chuo-ku, Tokyo, President: Tetsuya Mishima, …
Perseus Proteomics and Axcelead DDP launch a collaboration for an antibody drug discovery support service
Perseus Proteomics Inc. (Head office: Meguro, Tokyo; President …
ARCALIS and Axcelead DDP Announce Collaboration to Provide Integrated Drug Discovery Support Service for mRNA Therapeutics
TOKYO, JAPAN, 20 JULY 2022: ARCALIS Inc. (Head …
Axcelead DDP and Knowledge Palette Entered into a Collaborative Research Contract for Establishment of a New Evaluation Platform Using Axcelead DDP’s Compound Libraries and Large-Scale Transcriptome Analysis Technologies
Axcelead Drug Discovery Partners Inc. (headquarters: Fujisawa, Kanagawa; …